Compare Stocks: DTIL, CGEN, SLDB, and OSIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$2.45 -4.3%	$2.44	$1.29 ▼ $3.23	$232.97M	2.78	394,995 shs	23,605 shs
DTIL Precision BioSciences	$7.16 -3.3%	$7.85	$3.53 ▼ $9.62	$196.82M	1.24	320,972 shs	2,464 shs
OSIR Osiris Therapeutics	$18.99	$18.99	$7.01 ▼ $19.30	$655.69M	N/A	205,753 shs	N/A
SLDB Solid Biosciences	$9.30 -6.4%	$9.34	$3.79 ▼ $11.45	$996.07M	2.44	1.35 million shs	18,909 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	-3.13%	-5.70%	+5.98%	+21.57%	+73.43%
DTIL Precision BioSciences	-2.03%	-2.68%	-2.82%	+17.50%	+42.44%
OSIR Osiris Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
SLDB Solid Biosciences	-3.93%	-7.20%	+11.45%	+32.13%	+90.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$2.45 -4.3%	$2.44	$1.29 ▼ $3.23	$232.97M	2.78	394,995 shs	23,605 shs
DTIL Precision BioSciences	$7.16 -3.3%	$7.85	$3.53 ▼ $9.62	$196.82M	1.24	320,972 shs	2,464 shs
OSIR Osiris Therapeutics	$18.99	$18.99	$7.01 ▼ $19.30	$655.69M	N/A	205,753 shs	N/A
SLDB Solid Biosciences	$9.30 -6.4%	$9.34	$3.79 ▼ $11.45	$996.07M	2.44	1.35 million shs	18,909 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	-3.13%	-5.70%	+5.98%	+21.57%	+73.43%
DTIL Precision BioSciences	-2.03%	-2.68%	-2.82%	+17.50%	+42.44%
OSIR Osiris Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
SLDB Solid Biosciences	-3.93%	-7.20%	+11.45%	+32.13%	+90.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$5.00	104.08% Upside
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	350.73% Upside
OSIR Osiris Therapeutics	0.00	N/A	N/A	N/A
SLDB Solid Biosciences	2.83	Moderate Buy	$18.18	95.57% Upside

Current Analyst Ratings Breakdown

Latest DTIL, CGEN, SLDB, and OSIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $26.00
8/21/2026	SLDB Solid Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$16.00 ➝ $20.00
8/5/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/5/2026	DTIL Precision BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/4/2026	CGEN Compugen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SLDB Solid Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/9/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$72.76M	3.18	$0.36 per share	6.85	$1.09 per share	2.25
DTIL Precision BioSciences	$34.26M	5.76	N/A	N/A	$4.03 per share	1.78
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$2.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	$35.34M	$0.38	6.48	N/A	N/A	47.56%	42.57%	26.13%	11/9/2026 (Estimated)
DTIL Precision BioSciences	-$45.72M	-$2.80	N/A	N/A	N/A	-96.73%	-72.52%	-32.25%	11/2/2026 (Estimated)
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	-$174.32M	-$1.91	N/A	N/A	N/A	N/A	-71.35%	-60.58%	11/2/2026 (Estimated)

Latest DTIL, CGEN, SLDB, and OSIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A
8/6/2026	Q2 2026	SLDB Solid Biosciences	-$0.4624	-$0.38	+$0.0824	-$0.38	N/A	N/A
8/3/2026	Q2 2026	CGEN Compugen	-$0.08	-$0.07	+$0.01	-$0.07	$1.29 million	$2.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	5.72	5.72
DTIL Precision BioSciences	0.50	12.82	12.82
OSIR Osiris Therapeutics	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	13.82	13.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
DTIL Precision BioSciences	37.99%
OSIR Osiris Therapeutics	0.28%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
DTIL Precision BioSciences	2.70%
OSIR Osiris Therapeutics	43.40%
SLDB Solid Biosciences	2.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	94.55 million	85.57 million	Optionable
DTIL Precision BioSciences	200	27.60 million	26.86 million	No Data
OSIR Osiris Therapeutics	342	34.53 million	N/A	Not Optionable
SLDB Solid Biosciences	100	107.22 million	104.37 million	Optionable

DTIL, CGEN, SLDB, and OSIR Headlines

Recent News About These Companies

243,154 Shares in Solid Biosciences Inc. $SLDB Purchased by Bank of New York Mellon Corp

September 8 at 3:36 AM | marketbeat.com

Solid Biosciences to Participate at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Solid Biosciences (NASDAQ:SLDB) Price Target Raised to $26.00 at Cantor Fitzgerald

August 27, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Trading 5.5% Higher - Should You Buy?

August 25, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial

August 21, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 6.7% - Time to Sell?

August 20, 2026 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 20, 2026 | marketbeat.com

HC Wainwright Has Positive Estimate for SLDB Q3 Earnings

August 12, 2026 | marketbeat.com

Dimensional Fund Advisors LP Acquires 277,051 Shares of Solid Biosciences Inc. $SLDB

August 11, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Solid Biosciences (SLDB)

August 8, 2026 | theglobeandmail.com

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026 | finance.yahoo.com

Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)

July 7, 2026 | theglobeandmail.com

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

July 2, 2026 | seekingalpha.com

Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?

July 1, 2026 | finance.yahoo.com

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 1, 2026 | globenewswire.com

Solid Biosciences to Participate at Upcoming Investor Conferences

June 1, 2026 | globenewswire.com

J.P. Morgan Reaffirms Their Buy Rating on Solid Biosciences (SLDB)

May 24, 2026 | theglobeandmail.com

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

May 20, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), SELLAS Life Sciences Group (SLS) and Legend Biotech (LEGN)

May 14, 2026 | theglobeandmail.com

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

May 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, CGEN, SLDB, and OSIR Company Descriptions

Compugen NASDAQ:CGEN

$2.45 -0.11 (-4.30%)

As of 09:51 AM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Precision BioSciences NASDAQ:DTIL

$7.16 -0.25 (-3.31%)

As of 09:52 AM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Osiris Therapeutics OTCMKTS:OSIR

$18.99 0.00 (0.00%)

As of 04/17/2019

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Solid Biosciences NASDAQ:SLDB

$9.30 -0.63 (-6.37%)

As of 09:52 AM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DTIL, CGEN, SLDB, and OSIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DTIL, CGEN, SLDB, and OSIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DTIL, CGEN, SLDB, and OSIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, CGEN, SLDB, and OSIR Company Descriptions

Compugen NASDAQ:CGEN

Precision BioSciences NASDAQ:DTIL

Osiris Therapeutics OTCMKTS:OSIR

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DTIL, CGEN, SLDB, and OSIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DTIL, CGEN, SLDB, and OSIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DTIL, CGEN, SLDB, and OSIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, CGEN, SLDB, and OSIR Company Descriptions

Compugen NASDAQ:CGEN

Precision BioSciences NASDAQ:DTIL

Osiris Therapeutics OTCMKTS:OSIR

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools